Sumitomo Mitsui Trust Holdings Inc. Has $579.25 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sumitomo Mitsui Trust Holdings Inc. trimmed its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,451,414 shares of the medical equipment provider’s stock after selling 17,856 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Intuitive Surgical were worth $579,245,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ISRG. Baystate Wealth Management LLC boosted its holdings in shares of Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 45 shares during the period. MCF Advisors LLC boosted its stake in Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 40 shares during the period. Headinvest LLC bought a new stake in Intuitive Surgical in the 3rd quarter valued at $28,000. Able Wealth Management LLC bought a new position in Intuitive Surgical during the 4th quarter worth $28,000. Finally, Atticus Wealth Management LLC increased its position in Intuitive Surgical by 85.4% during the 4th quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 41 shares during the period. 83.64% of the stock is owned by institutional investors.

Insider Activity at Intuitive Surgical

In related news, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total value of $1,971,169.88. Following the sale, the executive vice president now directly owns 298 shares in the company, valued at $110,456.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Mark Brosius sold 175 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the completion of the sale, the senior vice president now owns 883 shares of the company’s stock, valued at $343,628.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Myriam Curet sold 5,318 shares of Intuitive Surgical stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the completion of the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $110,456.68. The disclosure for this sale can be found here. Insiders sold 17,956 shares of company stock worth $6,927,011 over the last three months. Company insiders own 0.80% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Piper Sandler upped their price target on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. Jefferies Financial Group increased their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Evercore ISI lifted their price target on shares of Intuitive Surgical from $385.00 to $425.00 and gave the company an “in-line” rating in a research report on Tuesday. Citigroup boosted their price target on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, Stifel Nicolaus raised their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Six investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $404.79.

Intuitive Surgical Price Performance

ISRG stock traded down $3.76 during midday trading on Wednesday, reaching $435.05. 88,405 shares of the stock were exchanged, compared to its average volume of 1,513,350. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $448.10. The company has a fifty day moving average price of $405.17 and a 200 day moving average price of $384.28. The stock has a market capitalization of $154.31 billion, a PE ratio of 79.21, a P/E/G ratio of 5.75 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm’s revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company earned $1.00 EPS. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.